Bitdeer Technologies Group vs Novavax Inc — how do they compare? Bitdeer Technologies Group trades at $9.19 (market cap $2.36B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Bitdeer Technologies Group is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| BTDR | NVAX | |
|---|---|---|
Market Cap | $2.36B | $1.31B |
Sector | Technology | Health |
52-Week High | $25.90 | $11.19 |
52-Week Low | $7.28 | $6.22 |
Enterprise Value | $3.85B | $889.30M |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $9.18, up 5.58% today but facing bearish technical signals with 13 of 13 moving averages indicating sell signals. The company reported Q2 2026 revenue growth but missed EPS expectations for the fourth consecutive quarter with a loss of $0.37 per share. Recent developments include a significant $4.7 billion AI data center deal announced August 4, 2026, signaling strategic expansion beyond Bitcoin mining into AI infrastructure.
Despite analyst optimism with 82% buy ratings and a $22.43 consensus price target, fundamental challenges persist including negative net income margin (-28.14%) and cash flow concerns. The stock offers substantial upside potential if AI initiatives succeed but faces execution risk amid volatile cryptocurrency markets and competitive pressures in the infrastructure sector.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Trailing returns across standard periods
Latest headlines on both assets
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →